- 5637 reports
Market Outlook and Forecast
Thelansis’s “Relapsed or Refractory Mycosis Fungoides (MF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Mycosis Fungoides treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Amblyopia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Amblyopia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Phelan-McDermid Syndrome (PMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential 22q13 deletion syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Lymphocytopenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lymphopenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pericarditis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Moderate to Severe Chronic Hand Eczema Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Chronic Hand Eczema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Keratoconus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Keratoconus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Current Treatment Insights
Thelansis’s “Alzheimer’s Disease (AD) Current Treatment Insights Report – 2025″ describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.
Market Access and Reimbursement Insights
Thelansis’s “Alzheimer’s Disease (AD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Alzheimer’s Disease (AD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Thelansis’s “Alzheimer’s Disease (AD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Epidemiology Insights and Forecast
Thelansis’s “Alzheimer’s Disease (AD) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Current Treatment Insights
Thelansis’s “Bipolar Depression Current Treatment Insights Report – 2025″ describes the current treatment and management in Bipolar depression. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.